Lirum Therapeutics, Inc. (LRTX)

Lirum Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022
Cash & Equivalents	4.01	0.17
Cash & Cash Equivalents	4.01	0.17
Cash Growth	2198.57%	-
Other Current Assets	0.56	0.24
Total Current Assets	4.57	0.41
Total Assets	4.57	0.41
Accounts Payable	0.8	0.23
Other Current Liabilities	1.38	1.6
Total Current Liabilities	2.18	1.83
Long-Term Debt	-	0.5
Total Long-Term Liabilities	0	0.5
Total Liabilities	2.18	2.33
Total Debt	0	0.5
Retained Earnings	-4.15	-1.95
Shareholders' Equity	2.39	-1.92
Net Cash / Debt	4.01	-0.33
Working Capital	2.39	-1.42

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).